Letter to Orexo shareholders from Chairman Martin Nicklasson

Uppsala, Sweden – December 19, 2013 - The Chairman of Orexo, Martin Nicklasson
has today sent a letter to all shareholders of Orexo AB. The letter provides an
update on the launch of Zubsolv® and the progress that the product is making in
the U.S. market. The letter is also available on the company's home page at
www.orexo.com.

For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 18-780 88 00, E-mail: ir@orexo.com

About Orexo
Orexo is an emerging specialty pharma company with commercial operations in the
United States and R&D in Sweden developing improved treatments using proprietary
drug delivery technology and commercial operations in the United States. The
company is commercializing its proprietary product, Zubsolv®, for maintenance
treatment of opioid dependence, in the United States. Zubsolv is a novel
formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in
sublingual technologies. Orexo has a portfolio of two approved and revenue
generating products currently marketed under license in the EU and US. Orexo AB,
with its headquarters in Sweden, is listed on NASDAQ OMX Stockholm Exchange and
its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the
U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and
HealthCap.

For more information about Orexo please visit www.orexo.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 2:15 pm CET on December 19, 2013.